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HOFFMANN·LA ROCHE INC. 
NUTl.EY e NEW JERSEY 07110 • TELEPHONE 1201) 23l5·l5000 • (N.Y.C.l 69l5·1400 
ROCHE RESEARCH CENTER 
January 4 ; 1988 
Dear Dr. 
Several of .us who are responsible for in:iustrial toxicology laboratories 
met sane time ago to review our activities for the use of alt;e.n,atives to 
animals for toxicity testi.n; an:l research. One of the out.cares of this 
rreetirq was a resolve to see that those alteJ::natives which had reached a 
practical level of use with orqoin; beneficial experience should be widely· 
?,lblicized so that our peers could take advantage of this experience. 
'Ihis letter is an invitation to share in the dissemination of this impor­
tant activity within our laboratories. We will contact you by :,;hone in 
the near future to confinn yoor potential irp.rt to the process. Research 
studies on the topic are of interest, b.1t there are ample opportunities to 
?,lblish· such procedures. We will be interested in those procedures that 
have becale part of your current practice with identifiable benefits rela­
tive to alteJ::natives. 
We also invite your direct response to this prcp::,sal with constructive 
criticism for its in1;,lementation. Several options have been discussed for 
the dissemination process, b.1t we will await your input _before de:::isions 
are made. 
A second o.ito:rne of our earlier meet.in; was an awareness of. the value of 
dialogue with. regulatory agencies. eur personal goal of reduction, re­
finement an:l replacement will oot be achieved in�that carp::,nent of our 
work subject to regulatory review if there are agency barriers to these 
alteJ::natives. Initial infarmal contacts have resulted in a favorable reac­
tion for an exchan;e of ideas. We would consider sett.in; it up in the 
Washin;ton area an:l inviting members of the regulatory agencies to atterx:i. 
We will keep you informed as plans develop. 
Sirx:erely yours, 
t�6f-+ 
E. A. Pfitzer 
Hoffmann-La Roche Inc. 
{?� ?2. �- A. scala
M::bil Oil Corporation Exxon Bianed.ical 
Sciences, Inc. 
